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Artificial image objects for classification
of breast cancer biomarkers with transcriptome
sequencing data and convolutional neural
network algorithms
Xiangning Chen1* , Daniel G. Chen1, Zhongming Zhao2,3, Justin M. Balko4,5,6 and Jingchun Chen7*

Abstract
Background: Transcriptome sequencing has been broadly available in clinical studies. However, it remains a challenge to utilize these data effectively for clinical applications due to the high dimension of the data and the highly
correlated expression between individual genes.
Methods: We proposed a method to transform RNA sequencing data into artificial image objects (AIOs) and applied
convolutional neural network (CNN) algorithms to classify these AIOs. With the AIO technique, we considered each
gene as a pixel in an image and its expression level as pixel intensity. Using the GSE96058 (n = 2976), GSE81538
(n = 405), and GSE163882 (n = 222) datasets, we created AIOs for the subjects and designed CNN models to classify
biomarker Ki67 and Nottingham histologic grade (NHG).
Results: With fivefold cross-validation, we accomplished a classification accuracy and AUC of 0.821 ± 0.023 and
0.891 ± 0.021 for Ki67 status. For NHG, the weighted average of categorical accuracy was 0.820 ± 0.012, and the
weighted average of AUC was 0.931 ± 0.006. With GSE96058 as training data and GSE81538 as testing data, the accuracy and AUC for Ki67 were 0.826 ± 0.037 and 0.883 ± 0.016, and that for NHG were 0.764 ± 0.052 and 0.882 ± 0.012,
respectively. These results were 10% better than the results reported in the original studies. For Ki67, the calls generated from our models had a better power for prediction of survival as compared to the calls from trained pathologists
in survival analyses.
Conclusions: We demonstrated that RNA sequencing data could be transformed into AIOs and be used to classify
Ki67 status and NHG with CNN algorithms. The AIO method could handle high-dimensional data with highly correlated variables, and there was no need for variable selection. With the AIO technique, a data-driven, consistent, and
automation-ready model could be developed to classify biomarkers with RNA sequencing data and provide more
efficient care for cancer patients.
Keywords: RNA sequencing, Breast cancer biomarker classification, Artificial image object, Artificial intelligence,
Machine learning algorithm, Convolutional neural network, Image classification
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Background
Breast cancer is a complex disease; early detection and
evaluation of the tumor are critical for prognosis and
long-term survival. Once a tumor is detected, histopathologic analyses with estrogen receptor, progesterone
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receptor, human epidermal growth factor receptor2, and
evaluation of Nottingham histologic grade (NHG) will be
performed. More recently, assessment of the proliferation
antigen Ki67 is increasingly recommended [1, 2]. These
biomarkers provide valuable prognostic information for
survival and treatment outcomes [3, 4]. Therefore, they
are used to guide therapeutic strategy selection. However, current approaches to evaluate these biomarkers, i.e., immunohistochemistry stains, require careful
assessments by trained pathologists, and disagreements
between the pathologists are often observed, especially
for NHG and Ki67. Other technical factors, such as sample fixation, antibody batches, and scoring methods, also
contribute to the inconsistent results. To obtain a consistent assessment, more robust methods that are amendable
to automation are highly desirable.
In recent years, technologies for transcriptome
sequencing have become stable and matured, and their
applications in clinics are steadily increasing. Some
researchers use RNA sequencing to discover new biomarkers; others use it to evaluate existing biomarkers.
Although the results vary, the assessment of many markers is comparable to that of histopathologic evaluation.
As more and more RNA sequencing data are accumulated, data-driven and machine learning (ML)-based
approaches have been explored to discover and classify
biomarkers [5–7]. Most of these methods use a variety of
strategies to select RNA variants (genes and transcripts)
and build classification models. One of the successful
examples is the establishment of PAM50 [8], where a collection of expressed genes is used to classify breast cancer into four different subtypes. One key issue in these
analyses is the selection of genes and transcripts. This
is because many genes are transcribed coordinately; the
high correlation between these genes and transcripts, i.e.,
multicollinearity, makes the selection necessary. Another
issue with biomarker discovery and modeling is that most
researchers focus on the identification of one, or a limited number, of markers that can be used to predict the
outcome measures. This is partially due to the fact that
traditional modeling approaches cannot handle a very
large number of variants, especially in the case where the
number of variants/factors is much larger than the number of observations/sample sizes.

The arise of modern computation power and ML algorithms provides an opportunity to address these issues.
Convolutional neural network (CNN) is such an algorithm that has been used very successfully in computer
vision and image classification [9, 10]. Recently, CNN
algorithms have been applied to classify medical images
with exciting results [11–13]. More recently, there are
several reports that apply CNN algorithms to the analyses of genomics data [14–16]. We have developed a technology that first transforms tabulated data into artificial
image objects (AIOs) and then applies ML algorithms
such as CNN to classify these AIOs [17]. In this study,
we apply the AIO technique to classify breast cancer biomarkers, with a focus on Ki67 and NHG that disagreements between pathologists are frequently observed. We
hope to demonstrate that a data-driven and ML-based
approach could produce consistent assignments for Ki67
and NHG. This report summarizes the results from the
study.

Methods
RNA sequencing data

We obtained three RNA sequencing datasets from the
NCBI GEO database (https://www.ncbi.nlm.nih.gov/
geo/), GSE81538 (n = 405), GSE96058 (n = 2976) [18]
and GSE163882 (n = 222). The GEO datasets provided
pathological assessments for the samples in the datasets
and RNA sequencing procedures, which were described
previously by the original authors [19]. GSE81538 and
GSE96058 were produced by a Swedish team using two
sequencing platforms, Hiseq2000 and NextSeq500.
GSE163882 was produced by a different team using the
NextSeq500 platform. For these datasets, the expression
data were measured by Fragments Per Kilobase Million
(FPKM). Table 1 summarizes the information of these
datasets. The inclusion of GSE163882 was to evaluate
the extent to which data produced from a different team
could impact on the model performance. After downloading the sequencing data from the GEO Database, a
logarithm (log2) transformation was performed for all
transcripts; then, the expression levels were rescaled to
a range between 0 and 255 for the transcripts. Official
gene symbols were extracted from the 3 datasets, and
the genes shared among the 3 datasets were used. This

Table 1 Descriptive summary of the datasets used in this study
Dataset

Ki67
Ki67−

NHG
Ki67+

Missing

Grade I

Grade II

Grade III

Missing

Survival day

Survival event

Sequencing platform

GSE96058

568

795

1613

449

1394

1074

59

2976

2976

GSE81538

231

174

0

48

167

190

0

0

0

Hiseq2000

0

0

0

17

74

131

0

0

0

NextSeq500

GSE163882

Hiseq2000/NextSeq500
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procedure generated a list of 16,889 genes. Since most
non-coding RNAs did not have official gene symbols, the
selected genes were mostly protein coding genes. From
this list, we used the first 16,384 genes (genes were sorted
by chromosome number and transcription starting position) to create a squared AIO for each of the patients.
The 16,384 genes could be configured as a 128 × 128 pixel
grayscale AIO or a 64 × 64 × 4 pixel colored AIO.
Clinical data

In this paper, we used the clinical information for Ki67
and NHG to create outcome measures or labels for our
model training and prediction. For the Ki67 label, we
used the pathologists’ consensus percentage of tumor
cells with Ki67 staining to create a binary label. Patients
with 20% or less cells stained with Ki67 antibody were
assigned as K
 i67− or 0; patients with more than 20% of
cells stained with Ki67 antibody were assigned as K
 i67+
or 1. Table 1 summarizes the number of subjects for
each category for the GSE81538 and GSE96058 datasets.
GSE163882 did not have information on Ki67. NHG had
3 grades, Grades I, II, and III, and they were labeled as 0,
1, and 2 in our model training. For the GSE96058 dataset,
there were chemotherapy, endocrine therapy, and survival data that could be used to evaluate the performance
of biomarkers. For the GSE163882 dataset, there were
only NHG data that could be used to evaluate our model
performance.
Transformation of RNA sequencing data into artificial
image objects (AIOs)

The AIO technique was based on the concept that considered each element in a dataset, such as a single nucleotide variation in genome wide association study, a gene/
transcript in RNA sequencing data, or a CpG locus in
methylation study, as a pixel in a digital image so that
we could use a collection of elements to create an AIO.
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With these AIOs, we could apply advanced AI and ML
algorithms to analyze and classify them. In this study, we
applied this technique to transcriptome sequencing data.
When the genes/transcripts were selected, we rescaled
the expression levels to a range between 0 and 255 for
each gene/transcript. For a given patient, the rescaled
expression level would be the pixel intensity of the AIO.
From the shared genes among the 3 datasets used in this
study, we used the first 16,384 genes (sorted by chromosome number and gene transcription start position) to
create an AIO for each of the patients in the datasets.
The 16,384 genes could be configured into two different image objects. One was a 128 × 128 (high × wide)
pixel grayscale AIO; the other was a 64 × 64 × 4 pixel
(high × wide × channel) pseudo-color AIO. The processes
to transform gene expression data into grayscale AIOs
are shown in Fig. 1. More specifically, for the 128 × 128
configuration, the first 128 genes from the sorted 16,384
list formed the first row of the AIO, and the next 128
genes formed the second row, and so on forward until the
last 128 genes formed the last row of the 128 × 128 AIO.
For the 64 × 64 × 4 configuration, the first 4096 genes
formed the first channel (layer) of the AIO, and the second 4096 genes formed the second channel, and so forth.
In these arrangements, the same gene from different individuals occupied the same coordinates on the AIOs, preserving the correlation among the genes as in the original
datasets. Therefore, conclusions derived from the classification of the AIOs would be the same as that from the
original expression data.
AIO classification and prediction with convolutional neural
network (CNN) algorithms

In this study, we used the TensorFlow (www.tensorflow.
org/) [20, 21], Keras (https://keras.io/api/) and the CNN
architecture [22, 23] to classify and predict AIOs generated from selected gene expression data. Once the AIOs

Fig. 1 A schematic drawing illustrating the process to transform tabulated gene expression data into AIOs. a Tabulated expression data in
normalized format. b Rescaling the expression data into the range of digital image (1 byte, 0–255). c Arranging the expression data from an
individual into an artificial image object (AIO). An AIO could be a grayscale image as shown here (d) or a colored image in which multiple layers of
data could be integrated into an AIO
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were made and labels (the calls from trained pathologists) were assigned to the subjects in the 3 datasets, the
Tensorflow and Keras platforms were used to conduct
image classification analyses. We conducted two sets of
analyses. Set I analyses were designed to evaluate how
well the whole transcriptome sequencing data could be
used to classify and predict the status of Ki67 and NHG.
The focus of these analyses was model performance. For
this purpose, we combined the GSE96058 and GSE81538
together and used five-fold cross validation with 80–20
splits to evaluate the performance of the models. These
analyses were referred to as cross-validation hereafter.
Set II analyses were intended to evaluate the generalizability, i.e., how well a model trained with one dataset
performed in an independent dataset. For these analyses,
we used those subjects with known Ki67 and NHG status
from the GSE96058 as training dataset and the subjects
from the GSE81538 and GSE163882 as testing datasets.
These analyses were referred to as sample testing hereafter. Once the models were trained, we used the models
to predict the status of Ki67 and NHG for those subjects with missing information in the GSE96058 dataset
(see Table 1). These subjects were then used for survival
analyses to compare the predictive performance between
model predicted calls and pathologist’s calls.
For the Ki67 binary phenotype, we reported binary
accuracy ([true positive + true negative]/[true positive + false positive + true negative + false negative]),
precision (true positive/[true positive + false positive]),
recall or sensitivity (true positive/[true positive + false
negative]), F1 score ([2 × precision × recall]/[precision + recall]) , and the area under the curve (AUC) of
the receiver operating characteristic (ROC) for the training process as defined in the scikit-learn package [24].
For the multi-class NHG classification, we reported categorical accuracy and class-specific AUC, precision, recall,
and F1 score. Weighted average accuracy and weighted
average of AUC were also reported for NHG, which were
the sum of the products of class frequency and classspecific accuracy/AUC for each class. For each model, we
performed at least 5 runs with slightly different hyperparameters such as learning rate, epsilon value, kernel regularizer values, and kernel size values and reported the
mean and standard deviation (sd) for these runs.
Survival analyses

Survival analyses were conducted with R packages “survival” (https://github.com/therneau/survival) and “survminer” (https://rpkgs.datanovia.com/survminer/index.
html), and the results were plotted with R package
“ggplot2” (https://ggplot2.tidyverse.org). We compared
the predictive performance of Ki67 and NHG status from
the pathologist’s calls with that of the calls predicted from
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our models. The p values reported were not corrected for
multiple comparisons.

Results
Model performance with five‑fold cross validation

With the combined GSE96058 and GSE81538 dataset,
we tested multiple CNN models to select model hyperparameters, such as the number of convolutional layers,
kernel size, regularizer sizes, learning rate, optimizers,
and number of fully connected layers. We found that a
CNN architecture (Fig. 2) with six 3 × 3 convolutional
layers followed with one 1 × 1 convolutional layer and
four fully connected layers produced good testing accuracy. The details of the hyperparameters used in the
models were included in the Python script posted at
our website (https://github.com/mdsamchen/AIO_scrip
ts.git). Figure 3a shows the training and testing AUCs
for Ki67, and Table 2 summarizes the detailed results
using the 64 × 64 × 4 configuration. For the cross-validation, we obtained a weighted average accuracy of
0.821 ± 0.023 and AUC of 0.891 ± 0.021. The precision,
recall and F1 score were 0.822 ± 0.023, 0.822 ± 0.024, and
0.822 ± 0.024, respectively (Table 2).
Similar to the Ki67 analyses, we performed five-fold
cross validation for NHG as well. Figure 3b shows the
class-specific AUCs for the 3 grades, and Table 3 summarizes the results. The performance of NHG was very close
to that of Ki67, the weighted average of categorical accuracy was 0.820 ± 0.012, and the weighted average of AUC
was 0.931 ± 0.006. The precision, recall, and F1 score
were 0.820 ± 0.012, 0.802 ± 0.033, and 0.804 ± 0.030,
respectively (Table 3).
Sample testing for the GSE81538 and GSE163882 datasets

In these analyses, we used the portion of the GSE96058
dataset that had Ki67 and NHG status as training samples to classify those patients in the GSE81538 and
GSE163882 datasets. The purpose was to evaluate the
generalizability of the model using independent training and testing datasets. Based on the results from
five-fold cross validation, we made slightly adjustments of the hyperparameters and did 5 or more runs
on the GSE81538 and GSE163882 datasets. As shown
in Table 2, the performances of sample testing results
were similar to that of five-fold cross validation for Ki67
when GSE81538 was used as independent testing dataset. The weighted accuracy for five-fold cross validation
was 0.821 ± 0.023; the weighted AUC was 0.891 ± 0.021.
In sample testing, the corresponding accuracy and
AUC were 0.826 ± 0.037 and 0.883 ± 0.016, respectively
(Table 2). For NHG, there were two testing 2 datasets,
GSE81538 and GSE163882. For GSE81538, the weighted
average of categorical accuracy and class-specific AUC
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Fig. 2 CNN model architecture used for five-fold cross validation. The model had two branches. On the left was a modified VGG structure, and on
the right was an embedding layer. The two branches were joined by concatenation before fully connected layers
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Fig. 3 Five-fold cross validation for biomarkers Ki67 and NHG. a Ki67,
the AUCs of the training and testing samples were shown. b NHG, the
class-specific AUCs for Grades I, II and III were shown

were 0.764 ± 0.052 and 0.882 ± 0.012, respectively
(Table 3), slightly worse than that obtained from five-fold
cross validation. However, for GSE163882 dataset, which
was produced by a different team, the performance was

significantly worse (weighted average of categorical accuracy = 0.580 ± 0.006 and weighted average of class-specific AUC = 0.587 ± 0.038). Compared to the multi-gene
models reported from the Sweden Cancerome Analysis
Network-Breast (SCAN-B) organization[18], the original
authors who produced and reported on the GSE81538
and GSE96058 datasets, our AIO approach performed
more than 10% better. In their report, the concordance
rate or accuracy for Ki67 was 0.663 and that for NHG
was 0.667, which were on par with the concordance rates
from trained pathologists.
The significantly worse performance of NHG on the
GSE163882 dataset surprised us. Therefore, we examined the dataset more carefully. We looked at the correlation of gene expressions, a technical measure of data
replicability, among the three datasets used in this study,
and we found that the correlation between GSE96058
and GSE81538 was good (Pearson correlation R = 0.99),
but that between GSE96058 and GSE163882 was moderate (R = 0.79), Additional file 1: Fig. S1. This suggested that the poor performance of the GSE163882 on
GSE96058 trained models was due to data inconsistency between the training and testing datasets. To further examine whether the structure of the model and
the genes used were able to classify NHG, we used the
GSE163882 alone and conducted five-fold cross validation with the same model structure. With the same genes
and only 222 subjects, we obtained a weighted average
accuracy of 0.813 ± 0.026 and weighted average AUC of
0.938 ± 0.007, Additional file 1: Table S1. The results were
virtually the same as that of the combined GSE96058
and GSE81538 dataset, suggesting that the structure of
the model and the selected genes was capable to classify
NHG.
Comparison between AIO configurations and CNN
architectures

The results above for both Ki67 and NHG were obtained
with AIOs using the 64 × 64 × 4 configuration. To

Table 2 Cross-validation and sample testing results for Ki67
Accuracy

AUC

0.821 ± 0.023

0.891 ± 0.021

0.826 ± 0.037

0.883 ± 0.016

Precision

Recall

F1-score

0.815 ± 0.036

0.834 ± 0.022

0.824 ± 0.026

0.822 ± 0.023

0.822 ± 0.024

0.822 ± 0.024

Cross-validation
Ki67Ki67 +

Weighted average
Sample testing on GSE81538

0.821 ± 0.023

0.891 ± 0.021

Ki67Ki67 +

Weighted average

0.826 ± 0.037

0.883 ± 0.016

0.831 ± 0.016

0.811 ± 0.036

0.820 ± 0.024

0.886 ± 0.010

0.796 ± 0.048

0.837 ± 0.021

0.833 ± 0.021

0.825 ± 0.036

0.825 ± 0.019

0.763 ± 0.036

0.864 ± 0.021

0.809 ± 0.016
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Table 3 Cross validation and sample testing results for NHG
Accuracya

AUCb

Precision

Recall

F1 Score

Cross validation
Grade I
Grade II
Grade III
Weighted average
Sample testing on GSE81538
Grade I
Grade II
Grade III
Weighted average
Sample testing on GSE163882
Grade I
Grade II
Grade III
Weighted average
a

Categorical accuracy, bclass-specific AUC

0.838 ± 0.085

0.809 ± 0.072

0.825 ± 0.038

0.820 ± 0.012
0.406 ± 0.081

0.743 ± 0.069

0.872 ± 0.029

0.764 ± 0.052
0±0

0.016 ± 0.006

0.974 ± 0.012

0.580 ± 0.006

0.974 ± 0.005

0.880 ± 0.012

0.938 ± 0.004

0.931 ± 0.006
0.873 ± 0.025

0.833 ± 0.005

0.928 ± 0.015

0.882 ± 0.012
0.622 ± 0.189

0.564 ± 0.044

0.596 ± 0.070

0.587 ± 0.038

evaluate whether and to what extent that AIO configuration influenced model performance, we did sample testing with the 128 × 128 configuration for the two markers.
The overall performances between the two configurations
were similar for both Ki67 and NHG (comparing Table 2
with Additional file 1: Table S2, and Table 3 with Additional file 1: Table S3). For example, the weighted average
accuracy for Ki67 was 0.826 ± 0.037 for the 64 × 64 × 4
configuration (Table 2), that for the 128 × 128 configuration was 0.825 ± 0.012 (Additional file 1: Table S2). Similarly, the weighted average of accuracies for NHG for the
two configurations were 0.764 ± 0.052 and 0.766 ± 0.009,
respectively. These results suggested that the configuration of the AIOs had minimal influence on model
performance.
We also compared the impact of CNN architectures
on classification performances. All results, up to this
point, were obtained with a two-dimension convolution
CNN architecture (2D-CNN). Since genes were arranged
on chromosomes linearly, we could treat gene expression as an one-dimensional data such that we could use
an one-dimension convolution CNN architecture (1DCNN) to classify the biomarkers. The results were summarized in Additional file 1: Tables S4 and S5. For Ki67,
the weighted average accuracy and AUC for 1D-CNN
were 0.803 ± 0.054 and 0.851 ± 0.019, which were very
close to the results obtained with 2D-CNN (0.826 ± 0.037
and 0.883 ± 0.016). For NHG, the weighted average accuracy and weighted average of AUC were 0.766 ± 0.009
and 0.880 ± 0.011 with 1D-CNN, and 0.764 ± 0.052
and 0.882 ± 0.012 with 2D-CNN, respectively. Again,

0.913 ± 0.028

0.686 ± 0.07

0.863 ± 0.031

0.820 ± 0.012
0.608 ± 0.116

0.710 ± 0.026

0.848 ± 0.022

0.762 ± 0.035
0±0

0.268 ± 0.133

0.589 ± 0.003

0.437 ± 0.045

0.838 ± 0.085

0.811 ± 0.072

0.756 ± 0.072

0.802 ± 0.033
0.408 ± 0.082

0.745 ± 0.070

0.873 ± 0.030

0.765 ± 0.052
0±0

0.016 ± 0.006

0.974 ± 0.012

0.330 ± 0.003

0.871 ± 0.037

0.738 ± 0.026

0.803 ± 0.031

0.804 ± 0.030
0.475 ± 0.059

0.725 ± 0.026

0.858 ± 0.015

0.758 ± 0.025
0±0

0.030 ± 0.010

0.734 ± 0.004

0.443 ± 0.004

we found that the differences between 1D-CNN and
2D-CNN were minimal.
Survival analyses for GSE96058 and GSE81538 subjects

The value of biomarkers in the care of breast cancer
patients was their ability to predict treatment outcomes
and survival rate. In addition to measure model accuracy
and AUC, another approach to evaluate the performance
of the models was to test whether the calls produced
from the models had similar predictive power as the calls
obtained from trained pathologists. Based on this rationale, we conducted comparative analyses using the subjects in the GSE96058 dataset. In the GSE96058 dataset,
there were 1363 subjects with pathologist assigned status
for Ki67, and there were 1613 subjects with missing data
for Ki67 status (Table 1). We used our model to predict
the Ki67 status for those subjects with missing status
and conducted survival analyses for these two groups of
subjects (Fig. 4). Comparing Fig. 4a with b, we could see
that the performance of model produced calls was better than that of the calls from trained pathologists, suggesting that with our CNN model, we could classify Ki67
status and achieve a better predictive power in survival
analyses than that obtained by trained pathologists (p
value < 0.0001 vs p value = 0.014). We conducted similar
analyses for the NHG. Since the number of subjects with
missing NHG status was very small (n = 59) compared
to the subjects with pathologist assigned NHG status
(n = 2917), we only saw a trend (p value = 0.09) for the
model produced calls (Fig. 4d).
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Fig. 4 Comparison of performance between pathologists’ consensus calls and model produced calls. a Survival analyses for pathologist’s
consensus calls of Ki67 status. b Survival analyses for model produced calls of Ki67 status. c Survival analyses for pathologist’s consensus calls of
NHG. d Survival analyses for model produced calls of NHG. For Ki67, the calls from the model had better performance in survival analyses than that
of pathologist’s consensus calls. For NHG, the performance of model produced calls only showed a trend, this was likely due to the much smaller
sample size (N = 59 as compared to N = 2917 from the pathologist’s calls, see Table 1)

Discussion
With the advancement of high-throughput DNA
sequencing technologies, transcriptome sequencing had
been used increasingly in clinical studies. The rapid accumulation of large transcriptome data presented a great
opportunity to apply ML algorithms to address clinical
issues. In this study, we adopted the CNN algorithms
to breast cancer RNA sequencing data and developed
models to classify two commonly used biomarkers. Our

goals were twofold: first, to evaluate the application of the
AIO technique to RNA sequencing data, and second, to
evaluate the performance of our CNN models with other
methods that were currently used for the classification of
breast cancer biomarkers. The reason we focused on Ki67
and NHG was that the assessments for these markers by
pathologists were not very consistent, improvement in
prediction accuracy was of high clinical value.
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We designed two sets of experiments to evaluate how
the combination of AIO technique and CNN algorithms
performed with RNA sequencing data for biomarker
classification. In the first experiment, we used cross validation techniques to assess the models built with the AIO
technique and CNN algorithms. Here we combined the
GSE96058 and GSE81538 datasets and performed fivefold cross validation for both Ki67 and NHG markers. For
Ki67, a binary classification, we accomplished an accuracy of 0.821 ± 0.023 and AUC of 0.891 ± 0.021 (Table 2).
The precision, recall, and F1 score were 0.822 ± 0.023,
0.822 ± 0.024, and 0.822 ± 0.024, respectively. For NHG,
a multi-class classification, the weighted average of categorical accuracy and the weighted average of class-specific AUC were 0.820 ± 0.012 and 0.931 ± 0.006 (Table 3).
In the second experiment, sample testing, we used
GSE96058 as training dataset to build the model and
tested its performance with independent GSE81538 and
GSE163882 datasets. We used GSE96058 as training data
because it had much larger sample size (n = 2976) compared to that of GSE81538 (n = 405). Both GSE96058
and GSE81538 were produced by a Swedish team [18,
19], and GSE163882 was produced by a different team.
For Ki67, the Swedish team reported a multi-gene model
with an accuracy of 0.663 as compared to the consensus calls from trained pathologists. Our model reported
an accuracy of 0.826 (Table 2). For NHG, the Swedish
team reported an accuracy of 0.677 and our CNN model
reported an accuracy of 0.764 (Table 3). For GSE163882,
our model trained with GSE96058 did not perform well,
with weighted accuracy of 0.580 ± 0.006 and weighted
AUC of 0.587 ± 0.038, respectively. To find the reason
why GSE163882 did not perform well, we looked at the
correlation of gene expressions between GSE96058 and
GSE163882, and we found that the correlation was not
very good (Pearson correlation coefficient, R = 0.79). As a
comparison, the correlation of gene expressions between
GSE96058 and GSE81538 was very good (R = 0.99)
(Additional file 1: Fig. S1). These analyses indicated that
the poor performance of GSE163882 was, at least in part,
due to the data inconsistency between the GSE96058 and
GSE163882 datasets. While both datasets were produced
with Illumina NextSeq500 platform, the technical details
how the sequencing was conducted could vary significantly. Furthermore, GSE96058 and GSE163882 used
a different sample treatment. GSE96058 used freshly frozen tissue samples, and GSE163882 used formalin-fixed
paraffin-embedded samples. All these contributed to the
inconsistent sequencing data. While the models trained
with GSE96058 did not perform well on GSE163882,
cross validation using only the GSE163882 data with the
same genes and CNN architecture did produce comparable accuracy (0.813 ± 0.026) and AUC (0.938 ± 0.007) as

Page 9 of 11

that of the combined GSE96058 and GSE81538 dataset
(compare Additional file 1: Table S1 and Table 3). These
results indicated that by transforming gene expression
data into AIOs, we could apply mature algorithms such
as CNN to effectively classify biomarkers and accomplish
comparable or better accuracy as compared to other
modeling methods. However, the significant performance
differences between GSE81538 and GSE163882 datasets
stressed the importance of data consistency. For a model
to have good generalizability and to be used in clinical
applications, it was critically important to establish stable and consistent pipelines for data production. The different performance of NHG between the GSE81538 and
GSE163882 datasets made it clear of this principle that
was well documented in the literature.
We evaluated how AIO configurations and CNN
architecture impacted on Ki67 and NHG classification.
The 16,384 genes could be configured into two different
image objects. For both grayscale 128 × 128 and pseudocolor 64 × 64 × 4 configurations, our models produced
similar classification accuracies (see Tables 2, 3, Additional file 1: Tables S2 and S3). This was consistent with
the results obtained from classification of black-white
and colored images in the field of computer vision. But
for the AIO technique, this was significant because this
suggested we could put different types of genomics data
into separate layers/channels and incorporated them into
an AIO, allowing integrated analyses with multi-omics
data. We also built models to classify Ki67 and NHG
using one-dimensional convolution, because genes were
aligned linearly on chromosomes, and conceptually,
they could be considered one-dimensional data suitable
for one-dimensional convolution analyses [15]. In our
analyses, 1D-CNN and 2D-CNN produced comparable
results (compare Tables 2 and 3 with Additional file 1:
Tables S4 and S5). Typically, 1D-CNN was used to analyze one-dimensional data, such as time series, audio,
text, and electrocardiogram data [25], and 2D-CNN was
used for computer vision and image classification. While
there were techniques transforming one-dimensional
data into images for 2D-CNN analyses [26], we were not
aware of extensive analyses to compare the performances
between 1D-CNN and 2D-CNN using the same data.
With our limited analyses, it would be difficult to conclude whether one approach was better than the other.
Researchers should explore both if the data could be analyzed with these algorithms.
We evaluated the predictive power of the calls produced from our CNN models by comparing it to that
of the consensus calls from trained pathologists. With
similar sample size (see Table 1), the Ki67 calls produced from our models had a better power in survival analyses than the calls from trained pathologists
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(Fig. 4a, b). The reason for this might be that model
produced calls were more consistent than human
raters. For NHG, with a very small sample size (n = 59),
the model produced calls showed a trend. Should we
have a larger sample size, the model produced calls
would produce significant results. These results demonstrated that once implemented, these models would
improve the productivity and consistency in clinical
applications.
In the literature, there was a report that proposed a
different method, DeepInsght, to transform non-image
data into images for CNN classification [16]. Both our
AIO technique and the DeepInsight enabled the application of CNN algorithms to non-image data and had
the potential to apply to large and multiple datasets.
But there was a key difference between our AIO technique and the DeepInsight. For the AIO technique, we
considered each feature/variable as a pixel, and directly
mapped the features onto the feature map. In contrast,
the DeepInsight approach first performed a kernel
PCA/tSNE transformation to determine the relationship among the features and then used this information to determine the coordinates of the features on the
image. After kernel PCA or tSNS transformation, not
only it could cause substantial loss of information, but
also created a situation where multiple features mapped
to the same coordinates on the transformed image. This
made it very difficult to track which features contributed the most to the patterns that the CNN algorithms
learned and used to classify the label, a piece of information that could be significant for understanding the
underlying biology when genomics data were used. This
ability to track the genes in the spatial patterns provided a new approach to discover multi-gene interactions and interaction networks. Given the differences
between the two methods, it would be interesting to
compare their performances using the same datasets.
Overall, both methods would have broad applications
in biomedical research.

Conclusions
In this article, we reported the application of a technique
to transform genomic data into AIOs and adopted CNN
algorithms for their classification. Applying the technique to Ki67 and NHG, biomarkers that had substantial
inconsistent assessments among trained pathologists, we
demonstrated that our CNN models achieved classification accuracies better than similar models reported in
the literature. Furthermore, with survival analyses, we
showed that the calls generated by the models had a better predictive power than the consensus calls made by
trained pathologists. These results illustrated the utility
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of the AIO technique in biomarker classification. With
the demonstration of the principle, the AIO technique
could have broad applications in clinical and genomics
studies, facilitating more effective care of cancer patients.
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